<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03455582</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2017/14</org_study_id>
    <nct_id>NCT03455582</nct_id>
  </id_info>
  <brief_title>Cognition Evolution and MRI Markers in PPMS Patients on 2 Years</brief_title>
  <acronym>PRO-COG</acronym>
  <official_title>Longitudinal Study of Cognition in Primary Progressive Multiple Sclerosis: a Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cognitive impairment is nowadays more and more recognized as an important feature of the&#xD;
      multiple sclerosis (MS) disease. Cognitive disorders frequency in MS is estimated between 40&#xD;
      and 60%. Cognitive impairment affects quality of life and vocational status in MS patients.&#xD;
&#xD;
      Until recently, little information was available on the cognitive dysfunction and their&#xD;
      evolution that occur in primary progressive multiple sclerosis (PPMS) as compared with&#xD;
      relapsing-remitting MS (RRMS). In PPMS pathological studies have shown the importance of&#xD;
      cortical demyelination and meningeal inflammation suggesting that the GM alteration could&#xD;
      play a major role in the cognitive impairment in this phenotype. The cognitive evolution and&#xD;
      the brain tissue alteration at the origin of these difficulties remain poorly understood in&#xD;
      PPMS. The use of new techniques for morphological and functional MRI can study the&#xD;
      contribution of diffuse White Matter (WM) alteration (probably through disconnexion of&#xD;
      relevant network) and diffuse Grey matter (GM) alterations in the cerebral cortex and other&#xD;
      structures (the hippocampi, the cerebellum, and the thalami) in cognitive impairment in PPMS&#xD;
      patients and on their evolution.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2018</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of composite z cognitive score based on individual neuropsychological scores</measure>
    <time_frame>At baseline (day 0) and at 24 months from baseline</time_frame>
    <description>The composite z cognitive score is the average of z individual cognitive scores. The score from each cognitive test is transformed into z-scores. Z-scores will be calculated for each cognitive score with the following formula: (patient's score - mean value of HC group matched for age, sex, and education level)/standard deviation of the matched HC for each evaluation time (baseline and 2 years).&#xD;
Individual neuropsychological scores included in composite z cognitive score : the Alertness subtest, the divided attention subtest and the visual-scanning subtest from the TAP, The Symbol-digit-modalities-test, the Paced-Auditory-Serial-Addition-Test 3s, reversed span, the Stroop test, the Verbal fluency, Trail Making test, the California Verbal memory learning test and the Brief visual memory test -revised</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of composite z cognitive score and ecological score with MRI parameters reflecting grey and white matter integrity and anatomic/functional connectivity</measure>
    <time_frame>At baseline (day 0) and at 24 months from baseline</time_frame>
    <description>The composite z cognitive score is the average of z individual cognitive scores. The score from each cognitive test is transformed into z-scores. Z-scores will be calculated for each cognitive score with the following formula: (patient's score - mean value of HC group matched for age, sex, and education level)/standard deviation of the matched HC for each evaluation time.&#xD;
The composite z ecological score is the average of z ecological scores of virtual reality task (Urban DailyCog©) and actual reality tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of composite z cognitive score based on individual neuropsychological scores</measure>
    <time_frame>At baseline (day 0), at 12 months and at 24 months from baseline</time_frame>
    <description>The composite z cognitive score is the average of z individual cognitive scores. The score from each cognitive test is transformed into z-scores. Z-scores will be calculated for each cognitive score with the following formula: (patient's score - mean value of HC group matched for age, sex, and education level)/standard deviation of the matched HC for each evaluation time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of composite z ecological score based on individual ecological scores</measure>
    <time_frame>At baseline (day 0), at 12 months and at 24 months from baseline</time_frame>
    <description>The composite z cognitive score is the average of z individual cognitive scores. The score from each cognitive test is transformed into z-scores. Z-scores will be calculated for each cognitive score with the following formula: (patient's score - mean value of HC group matched for age, sex, and education level)/standard deviation of the matched HC for each evaluation time. The composite z ecological score is the average of z ecological scores of virtual reality task (Urban DailyCog©) and actual reality tests.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Multiple Sclerosis, Primary Progressive</condition>
  <arm_group>
    <arm_group_label>patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PPMS diagnosis according to McDonald 2010 criteria (Polman et al, 2011)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 Healthy controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical assessment</intervention_name>
    <description>Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.</description>
    <arm_group_label>patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ecological evaluation</intervention_name>
    <description>Virtual reality task and Actual reality</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neuropsychological evaluation</intervention_name>
    <description>cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Psychological evaluation</intervention_name>
    <description>questionnaires for depression, anxiety and fatigue</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI Evaluation</intervention_name>
    <description>morphological MRI and resting state functional MRI (fMRI)</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        PATIENTS&#xD;
&#xD;
          -  Male or female;&#xD;
&#xD;
          -  Age ≥ 18 years;&#xD;
&#xD;
          -  PPMS diagnosis according to McDonald 2010 criteria;&#xD;
&#xD;
          -  Disease duration ≤ 10 years;&#xD;
&#xD;
          -  Native French speaking;&#xD;
&#xD;
          -  Being affiliated to health insurance;&#xD;
&#xD;
          -  Willing to participate and to sign informed consent.&#xD;
&#xD;
        HEALTHY CONTROLS&#xD;
&#xD;
          -  Male or Female;&#xD;
&#xD;
          -  Age ≥ 18 years;&#xD;
&#xD;
          -  Native French speaking;&#xD;
&#xD;
          -  Being affiliated to health insurance;&#xD;
&#xD;
          -  Willing to participate and to sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        PATIENTS&#xD;
&#xD;
          -  previous history of other neurological disease;&#xD;
&#xD;
          -  psychiatric comorbidity including severe depression according to DSM-IV;&#xD;
&#xD;
          -  alcohol or other addiction to toxic;&#xD;
&#xD;
          -  disabling visual or motor problems preventing participation to neuropsychological&#xD;
             assessments;&#xD;
&#xD;
          -  change of psychotropic drug since less than one month;&#xD;
&#xD;
          -  contra-indication to MRI (pacemakers, aneurysm clips, artificial heart valves, ear&#xD;
             implants, metal fragments or foreign objects in the eyes, skin or body,claustrophobia&#xD;
             or refusing MRI);&#xD;
&#xD;
          -  illiteracy, is unable to count or to read;&#xD;
&#xD;
          -  pregnant or breastfeeding women;&#xD;
&#xD;
          -  patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty&#xD;
             by a judicial or administrative decision, minors, persons of legal age who are the&#xD;
             object of a legal protection measure or unable to express their consent).&#xD;
&#xD;
        HEALTHY CONTROLS&#xD;
&#xD;
          -  history of neurological disease;&#xD;
&#xD;
          -  family history of MS;&#xD;
&#xD;
          -  psychiatric comorbidity including severe depression according to DSM-IV;&#xD;
&#xD;
          -  alcohol or other toxic addiction;&#xD;
&#xD;
          -  psychotropic drugs; known cognitive complaint or neuropsychological affection;&#xD;
&#xD;
          -  prior neuropsychological testing with the same tests less than 6 months&#xD;
&#xD;
          -  contra-indication to MRI (pacemakers, aneurysm clips, artificial heart valves, ear&#xD;
             implants, meta fragments or foreign objects in the eyes, skin or body, claustrophobia&#xD;
             or refusing MRI);&#xD;
&#xD;
          -  illiteracy, is unable to count or to read;&#xD;
&#xD;
          -  pregnant or breastfeeding women;&#xD;
&#xD;
          -  person concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty&#xD;
             by a judicial or administrative decision, minors, persons of legal age who are the&#xD;
             object of a legal protection measure or unable to express their consent).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aurélie RUET, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aurélie RUET, Prof</last_name>
    <phone>05 56 79 55 21</phone>
    <phone_ext>+33</phone_ext>
    <email>aurelie.ruet@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mathilde DELOIRE, PhD</last_name>
    <phone>05 57 82 12 75</phone>
    <phone_ext>+33</phone_ext>
    <email>mathilde.deloire@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurelie RUET, Prof</last_name>
      <phone>05 56 79 55 21</phone>
      <phone_ext>+33</phone_ext>
      <email>aurelie.ruet@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Mathilde DELOIRE, PhD</last_name>
      <phone>05 57 82 12 75</phone>
      <phone_ext>+33</phone_ext>
      <email>mathilde.deloire@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Bruno BROCHET, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurélie RUET, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis MONTCUQUET, MD</last_name>
      <email>a.montcuquet@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alexis MONTCUQUET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Philippe NEAU, Prof</last_name>
      <email>jph.neau@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Philippe NEAU, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 4, 2018</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2018</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cognitive impairment</keyword>
  <keyword>ecological assessment</keyword>
  <keyword>brain MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

